• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical development of vascular disrupting agents: what lessons can we learn from ASA404?

作者信息

Lorusso Patricia M, Boerner Scott A, Hunsberger Sally

出版信息

J Clin Oncol. 2011 Aug 1;29(22):2952-5. doi: 10.1200/JCO.2011.36.1311. Epub 2011 Jun 27.

DOI:10.1200/JCO.2011.36.1311
PMID:21709201
Abstract
摘要

相似文献

1
Clinical development of vascular disrupting agents: what lessons can we learn from ASA404?血管破坏剂的临床开发：我们能从 ASA404 中学到什么经验教训？
J Clin Oncol. 2011 Aug 1;29(22):2952-5. doi: 10.1200/JCO.2011.36.1311. Epub 2011 Jun 27.
2
Modulation of chemotherapeutic efficacy by vascular disrupting agents: optimizing the sequence and schedule.血管破坏剂对化疗疗效的调节：优化给药顺序和方案
J Clin Oncol. 2012 Mar 1;30(7):760-1; author reply 761-3. doi: 10.1200/JCO.2011.39.3934. Epub 2012 Jan 30.
3
Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions.在实体瘤治疗中，将贝伐单抗添加到化疗方案中：结果相似但结论不同。
J Clin Oncol. 2011 Jan 20;29(3):254-6. doi: 10.1200/JCO.2010.32.0275. Epub 2010 Dec 13.
4
[Are antiangiogenic antibodies universal for solid tumor?].抗血管生成抗体对实体瘤是否具有普遍性？
Bull Cancer. 2007 Jul;94 Spec No:S191-6.
5
Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.卡铂和紫杉醇联合或不联合血管破坏剂vadimezan（ASA404）治疗晚期非小细胞肺癌的随机 III 期安慰剂对照试验。
J Clin Oncol. 2011 Aug 1;29(22):2965-71. doi: 10.1200/JCO.2011.35.0660. Epub 2011 Jun 27.
6
Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.使用基于抗体的疗法靶向血管内皮生长因子驱动的血管生成。
Cancer J. 2008 May-Jun;14(3):170-7. doi: 10.1097/PPO.0b013e318178d9de.
7
The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities.肿瘤血管破坏剂 ASA404（vadimezan，DMXAA）的开发：现状与未来机遇。
Expert Opin Investig Drugs. 2010 Feb;19(2):295-304. doi: 10.1517/13543780903540214.
8
Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.研究贝伐单抗在其他适应症中的潜力：转移性肾细胞癌、非小细胞肺癌、胰腺癌和乳腺癌。
Oncology. 2005;69 Suppl 3:46-56. doi: 10.1159/000088483. Epub 2005 Nov 21.
9
Anti-angiogenesis drugs in lung cancer.抗血管生成药物在肺癌中的应用。
Respirology. 2010 Apr;15(3):387-92. doi: 10.1111/j.1440-1843.2010.01715.x. Epub 2010 Mar 19.
10
Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer.抗血管生成药物在非小细胞肺癌患者中的获益和局限性。
Lung Cancer. 2010 Dec;70(3):233-46. doi: 10.1016/j.lungcan.2010.08.018.

引用本文的文献

1
Mechanisms of resistance to anti-angiogenic treatments.抗血管生成治疗的耐药机制。
Cancer Drug Resist. 2019 Sep 19;2(3):595-607. doi: 10.20517/cdr.2019.39. eCollection 2019.
2
Co-administration of combretastatin A4 nanoparticles and anti-PD-L1 for synergistic therapy of hepatocellular carcinoma.考布他汀 A4 纳米粒联合抗 PD-L1 协同治疗肝细胞癌。
J Nanobiotechnology. 2021 May 1;19(1):124. doi: 10.1186/s12951-021-00865-w.
3
Glioblastoma: Targeting Angiogenesis and Tyrosine Kinase Pathways.胶质母细胞瘤：靶向血管生成和酪氨酸激酶途径
Nov Approaches Cancer Study. 2020;4(5):398-401. Epub 2020 May 29.
4
MRI Monitoring of Cerebral Blood Flow after the Delivery of Nanocombretastatin across the Blood Brain Tumor Barrier.纳米考布他汀穿过血脑肿瘤屏障后脑部血流的磁共振成像监测
J Nanomed Nanotechnol. 2018;9(5). doi: 10.4172/2157-7439.1000516. Epub 2018 Oct 25.
5
B cell MHC class II signaling: A story of life and death.B细胞MHC II类信号传导：生与死的故事。
Hum Immunol. 2019 Jan;80(1):37-43. doi: 10.1016/j.humimm.2018.04.013. Epub 2018 Apr 30.
6
Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies - A review.用于实体瘤治疗的抗血管生成药物：潜在途径、治疗方法及当前策略——综述
J Adv Res. 2017 Nov;8(6):591-605. doi: 10.1016/j.jare.2017.06.006. Epub 2017 Jun 27.
7
Natural products against cancer angiogenesis.对抗癌症血管生成的天然产物。
Tumour Biol. 2016 Nov;37(11):14513-14536. doi: 10.1007/s13277-016-5364-8. Epub 2016 Sep 20.
8
Hepatocellular Carcinoma: Intra-arterial Delivery of Doxorubicin-loaded Hollow Gold Nanospheres for Photothermal Ablation-Chemoembolization Therapy in Rats.肝细胞癌：载有多柔比星的中空金纳米球经动脉给药用于大鼠光热消融 - 化疗栓塞治疗
Radiology. 2016 Nov;281(2):427-435. doi: 10.1148/radiol.2016152510. Epub 2016 Jun 27.
9
Advances in targeted and immunobased therapies for colorectal cancer in the genomic era.基因组时代结直肠癌靶向治疗和免疫治疗的进展
Onco Targets Ther. 2016 Mar 31;9:1899-920. doi: 10.2147/OTT.S95101. eCollection 2016.
10
Phenotype-based Discovery of 2-[(E)-2-(Quinolin-2-yl)vinyl]phenol as a Novel Regulator of Ocular Angiogenesis.基于表型发现2-[(E)-2-(喹啉-2-基)乙烯基]苯酚作为眼部血管生成的新型调节剂
J Biol Chem. 2016 Apr 1;291(14):7242-55. doi: 10.1074/jbc.M115.710665. Epub 2016 Feb 4.